Breaking News

CTI Acquires Community Research

By Kristin Brooks | February 3, 2014

Adds three locations and expands service offerings

CTI Clinical Trial and Consulting Services (CTI) has acquired Community Research, a specialty clinical research site with three locations throughout Cincinnati, OH. Community Research conducts Phase I-IV trials in various therapeutic areas, including internal medicine, dermatology, psychiatry, and sleep disorders. Its hospital-based Phase I facility can accommodate drug and device trials, with a special focus on first-in-human studies in various patient populations.  Financial terms were not disclosed.
David Mayleben, Ph.D., president and co-founder of Community Research, will serve as vice president at CTI, and will continue to lead the research centers. Co-founder, Dr. Bruce Corser, will serve as a consultant for CTI. Community Research’s 50 employees will join CTI.
“This is a great opportunity to strengthen the offerings that Community Research provides to those in the pharmaceutical and biotechnology industries,” said Dr. Mayleben. “We have worked with CTI many times over the past several years and are excited for this new endeavor.”
“We are looking forward to the integration of both companies and adding the strong operational expertise Community Research has to our own organization,” said Kevin Schwarz, chief operating officer of CTI. “We feel that Community Research provides us with even greater service offerings for our clients, who include more than 70 pharmaceutical and biotechnology companies around the world.”

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research